EUVIMEDEUVIMED entdecken
Crossref

Prevalence of Adeno-Associated Virus-9-Neutralizing Antibody in Chinese Patients with Duchenne Muscular Dystrophy

Cuijie Wei, Dongliang Li, Meng Zhang, Yanping Zhao, Yidan Liu, Yanbin Fan, Lu Wang, Jieyu Liu, Xingzhi Chang, Yuwu Jiang, Hui Xiong

Human Gene Therapy · 2024

DOI: 10.1089/hum.2023.117 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Gene Therapy, 2024. Verfasst von Cuijie Wei und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Peking University First Hospital, Beijing, P.R. China. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The delivery of a mini-dystrophin gene to skeletal muscles using recombinant adeno-associated virus serotype (AAV) holds great potential as a gene therapy for Duchenne muscular dystrophy (DMD). However, the presence of anti-AAV-neutralizing antibodies (NAbs) may impede the effectiveness of gene transduction. This study aimed to evaluate the prevalence of anti-AAV9 NAbs in Chinese patients with DMD, and to characterize the target population for an AAV gene therapy. A total of one hundred male patients with DMD were included in this study, and demographic and clinical data were collected. A blood specimen was obtained from each participant for the purpose of evaluating the existence of anti-AAV9 NAbs through a cell-based functional assay conducted at a central laboratory. A NAb titer exceeding 1:4 was considered positive. The positivity rates of anti-AAV9 NAb were compared among different subgroups. The median age of this DMD cohort was 8 years old, ranging from 3 to 15 years of age. Forty-two percent of patients tested positive for anti-AAV9 NAb. Notably, all samples from patients under 4 years of age tested negative, and the positivity rates of anti-AAV9 NAb differed significantly across the three age subgroups (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, DuchenneChildHumansMaleChild, PreschoolDependovirusPrevalenceDystrophinAntibodies, NeutralizingChinaGenetic Vectors

Stichwörter der Autor:innen

Duchenne muscular dystrophyadeno-associated virus serotype 9gene therapyneutralizing antibodyprevalence

Substanzen

DystrophinAntibodies, Neutralizing

Autor:innen und Institutionen

  • Department of Pediatrics, Peking University First Hospital, Beijing, P.R. China.

Zitieren

APA

Wei, C., Li, D., Zhang, M., Zhao, Y., Liu, Y., Fan, Y., Wang, L., Liu, J., Chang, X., Jiang, Y., & Xiong, H. (2024). Prevalence of Adeno-Associated Virus-9-Neutralizing Antibody in Chinese Patients with Duchenne Muscular Dystrophy. Human Gene Therapy. https://doi.org/10.1089/hum.2023.117

Vancouver

Wei C, Li D, Zhang M, Zhao Y, Liu Y, Fan Y, et al. Prevalence of Adeno-Associated Virus-9-Neutralizing Antibody in Chinese Patients with Duchenne Muscular Dystrophy. Human Gene Therapy. 2024. doi:10.1089/hum.2023.117

BibTeX
@article{Wei2024,
  author = {Wei, Cuijie and Li, Dongliang and Zhang, Meng and Zhao, Yanping and Liu, Yidan and Fan, Yanbin and Wang, Lu and Liu, Jieyu and Chang, Xingzhi and Jiang, Yuwu and Xiong, Hui},
  title = {Prevalence of Adeno-Associated Virus-9-Neutralizing Antibody in Chinese Patients with Duchenne Muscular Dystrophy},
  journal = {Human Gene Therapy},
  year = {2024},
  doi = {10.1089/hum.2023.117}
}
Kostenlos starten →